Redbiotec AG

Redbiotec is a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH Zurich), the company has won several awards, including the renowned W.A. De Vigier Award. Backed by internationally recognized scientists as Scientific Advisors, the company has a dedicated scientific team with expertise in multiple disciplines from immunology and microbial engineering to protein engineering.

Presently, Redbiotec is developing immunotherapies for cancer and herpes:

1. HSV-2 immunotherapy program, which builds upon our prior success in vaccine development that led to Pfizer's acquisition of our CMV vaccine program.

2. Living medicines programs based on proprietary engineered bacteria: a) Immuno-oncology therapy combining oncolytic virus with engineered bacteria to turn "cold" tumours hot. Our lead candidate is RONC1, for treating pancreatic cancer b) Gene therapy delivery using engineered bacteria. Our lead candidate is RONC3, for treating HPV-mediated cervical cancer

We actively evaluate partnering opportunities with the ultimate goal of reinforcing our portfolio, and/or to add value to the therapies developed by our collaboration partners, in order to meet unmet patient needs. We welcome strategic partnerships to further the development of our preclinical assets and to increase the impact of our technology platforms.